MindWalk Holdings Appoints R. Scott Areglado as Chief Financial Officer to Advance Financial Strategy and Support Global Growth
MINNEAPOLIS, MN – October 23, 2025 – MindWalk Holdings Corp.™ (“MindWalk,” “the Company,” “we,” or “us”) (Nasdaq: HYFT), a bio-native artificial intelligence (AI) company pioneering AI-driven solutions for life sciences, today announced the appointment of R. Scott Areglado as Chief Financial Officer (CFO), effective October 20, 2025.
Areglado joins MindWalk with more than 25 years of financial leadership experience across the healthcare, life sciences, and technology sectors. His proven expertise in corporate finance, strategic planning, capital markets, and investor relations for publicly traded companies will play a pivotal role as MindWalk advances its Bio-Native AI platform globally.
Scott’s extensive background guiding financial strategy for high-growth, publicly traded healthcare and technology companies makes him an outstanding addition to our executive leadership team,” said Dr. Jennifer Bath, Chief Executive Officer of MindWalk. “His ability to strengthen financial systems, implement disciplined growth initiatives, and communicate effectively with the investment community will be instrumental as we continue scaling MindWalk’s Bio-Native AI solutions worldwide.
Financial Leadership Experience Across Growth-Focused Sectors
Mr. Areglado brings a distinguished record of leading financial transformation and driving sustained revenue growth across innovative healthcare and technology organizations. Over the course of his career, he has demonstrated a consistent ability to optimize capital allocation, enhance operational efficiency, and execute complex strategic transactions that create shareholder value.
Most recently, Areglado served as Chief Financial Officer of BrainsWay Ltd. (Nasdaq: BWAY), a global leader in interventional psychiatry. During his tenure, he was instrumental in redefining corporate strategy, implementing enhanced financial discipline, and overseeing eight consecutive quarters of revenue growth. Under his financial stewardship, BrainsWay expanded analyst coverage and strengthened investor engagement, improving the company’s visibility and credibility within the capital markets.
Prior to BrainsWay, Areglado served as Chief Financial Officer at iCAD, Inc. (Nasdaq: ICAD), a medical technology company specializing in AI-powered cancer detection and therapy solutions. There, he successfully executed multiple financings totaling over $50 million, supported strategic partnerships, and guided acquisitions that expanded the company’s product portfolio and competitive position. His leadership helped strengthen iCAD’s financial foundation and advance its mission to bring next-generation cancer solutions to market.
Earlier in his career, Areglado held senior financial positions at AMICAS, Inc. (Nasdaq: AMCS) and several emerging technology enterprises, where he developed deep expertise in SEC reporting, M&A integration, and operational transformation. He began his professional career in public accounting, establishing a strong grounding in financial controls and corporate governance. Mr. Areglado holds a Master of Business Administration from Babson College and a Bachelor of Business Administration in Accounting from the University of Massachusetts Amherst.
A Vision for Financial Excellence in Bio-Native AI
Commenting on his appointment, Mr. Areglado said:
MindWalk represents an exceptional opportunity to combine financial leadership with transformative innovation in the rapidly evolving field of Bio-Native AI. The Company is uniquely positioned to redefine how artificial intelligence is integrated into life sciences, and I am excited to contribute to that mission. I look forward to partnering with Dr. Bath and the entire MindWalk team to drive disciplined growth, expand our global reach, and build long-term value for shareholders.
As CFO, Mr. Areglado will oversee all aspects of MindWalk’s financial strategy, including financial planning and analysis, accounting, investor relations, risk management, and capital markets activity. He will work closely with the leadership team and Board of Directors to strengthen MindWalk’s financial infrastructure and ensure alignment with the Company’s long-term growth objectives.
Annual General Meeting Results and Board Update
MindWalk also announced the results of its 2025 Annual General Meeting of Shareholders (AGM), held on October 9, 2025.
At the meeting, shareholders re-elected Dr. Jennifer Bath, Jon Lieber, and Dirk Witters to the Company’s Board of Directors. In addition, Davidson & Company LLP was re-appointed as the Company’s auditor for the ensuing fiscal year.
In accordance with MindWalk’s Majority Voting Policy, Mr. Kamil Isaev—who received approximately 32% of votes in favor and 68% withheld for his re-election—tendered his resignation to the Board. The Board has accepted Mr. Isaev’s resignation, effective immediately.
On behalf of the Board and management, we extend our sincere gratitude to Kamil for his valuable contributions and dedication throughout MindWalk’s transformation into a global Bio-Native AI leader,” said Dr. Bath. “We wish him continued success in his future endeavors.
The Board of Directors has initiated a search process to identify and appoint a successor to fill the resulting vacancy. The Company will provide an update once a new director has been selected, consistent with MindWalk’s governance framework and regulatory disclosure obligations.
MindWalk will file the complete voting results of the 2025 AGM on SEDAR+ in Canada and on Form 6-K with the U.S. Securities and Exchange Commission (SEC).
About MindWalk Holdings Corp.™
MindWalk Holdings Corp.™ (Nasdaq: HYFT) is a bio-native AI company leveraging the power of artificial intelligence to transform life sciences, biotechnology, and healthcare innovation. By integrating advanced AI models with biological and molecular data, MindWalk enables faster discovery, smarter design, and more effective decision-making across the drug development and health ecosystems.
MindWalk’s Bio-Native AI platform is designed to augment human expertise, accelerate R&D, and improve the efficiency of scientific and clinical outcomes. The Company is committed to pioneering new standards in bio-AI integration that drive measurable value for partners, patients, and shareholders alike.
For additional information, please visit www.mindwalkai.com.
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements reflect management’s current expectations regarding future events and operational performance and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, but are not limited to, the Company’s ability to execute its growth strategy, integrate new leadership effectively, and maintain financial and operational performance. MindWalk undertakes no obligation to update or revise any forward-looking statements, except as required by law.
